Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameZhaoke Ophth-B
Stock Code06622
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities眼科製藥公司,致力於療法的研究、開發及商業化,擁有包含25種候選藥物的全面眼科藥物管線,涵蓋眼前節及眼後節多數主要眼科適應症,並建立先進眼藥製造設施及營銷團隊。
Listing Date2021-04-29
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國廣東省廣州市南沙區珠江工業園美德三路1號
Business Address (Hong Kong)香港沙田香港科學園3期12W座7樓716室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitezkoph.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 16.80 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 8,400
Par ValueTo be extracted
Offer Period2021-04-16 to 2021-04-21
Global Offering Shares123,567,500 shares
HK Public Offer Shares (Initial)12,357,000 shares (10.0%)
Public Offer Lots (Initial)24,714lots (Pool A12,357lots,Pool B12,357lots)
International Placing Shares (Initial)111,210,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO535,155,500 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share20.6%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 2,075,934,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 8,400
1 lots 500 HK$ 8,400
2 lots 1,000 HK$ 16,800
2 lots 1,000 HK$ 16,800
3 lots 1,500 HK$ 25,200
4 lots 2,000 HK$ 33,600
5 lots 2,500 HK$ 42,000
5 lots 2,500 HK$ 42,000
6 lots 3,000 HK$ 50,400
6 lots 3,000 HK$ 50,400
7 lots 3,500 HK$ 58,800
8 lots 4,000 HK$ 67,200
9 lots 4,500 HK$ 75,600
10 lots 5,000 HK$ 84,000
12 lots 6,000 HK$ 100,800
12 lots 6,000 HK$ 100,800
14 lots 7,000 HK$ 117,600
14 lots 7,000 HK$ 117,600
16 lots 8,000 HK$ 134,400
18 lots 9,000 HK$ 151,200
20 lots 10,000 HK$ 168,000
30 lots 15,000 HK$ 252,000
30 lots 15,000 HK$ 252,000
40 lots 20,000 HK$ 336,000
50 lots 25,000 HK$ 420,000
50 lots 25,000 HK$ 420,000
60 lots 30,000 HK$ 504,000
60 lots 30,000 HK$ 504,000
70 lots 35,000 HK$ 588,000
70 lots 35,000 HK$ 588,000
80 lots 40,000 HK$ 672,000
80 lots 40,000 HK$ 672,000
90 lots 45,000 HK$ 756,000
100 lots 50,000 HK$ 840,000
100 lots 50,000 HK$ 840,000
120 lots 60,000 HK$ 1,008,000
140 lots 70,000 HK$ 1,176,000
160 lots 80,000 HK$ 1,344,000
180 lots 90,000 HK$ 1,512,000
200 lots 100,000 HK$ 1,680,000
300 lots 150,000 HK$ 2,520,000
400 lots 200,000 HK$ 3,360,000
500 lots 250,000 HK$ 4,200,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 300,000 HK$ 5,040,000
700 lots 350,000 HK$ 5,880,000
800 lots 400,000 HK$ 6,720,000
900 lots 450,000 HK$ 7,560,000
1,000 lots 500,000 HK$ 8,400,000
1,200 lots 600,000 HK$ 10,080,000
1,400 lots 700,000 HK$ 11,760,000
1,600 lots 800,000 HK$ 13,440,000
1,800 lots 900,000 HK$ 15,120,000
2,000 lots 1,000,000 HK$ 16,800,000
4,000 lots 2,000,000 HK$ 33,600,000
6,000 lots 3,000,000 HK$ 50,400,000
8,000 lots 4,000,000 HK$ 67,200,000
10,000 lots 5,000,000 HK$ 84,000,000
10,486 lots 5,243,350 HK$ 88,088,280
12,357 lots 6,178,500 HK$ 103,798,800

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.46B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +543%

Valuation & Financials

Market Cap (at Offer Price)HK$ 8,990,612,400
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣727.0百萬元
Period-End Cash Balance人民幣65.1百萬元
Listing Expenses~HK$ 130,444,000
Listing Expenses / Funds Raised~6.28%
Total Pre-IPO Investment人民幣1310.7百萬元

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Profit for the year -122,077-726,981
Balance Sheet
Item 20192020
Cash and cash equivalents 154,76965,096
Total current assets 379,607913,623
Total assets 554,2141,226,586
Total current liabilities 183,83453,666
Total liabilities 579,7461,972,554
Total equity -25,532-745,968
Interest-bearing borrowings 010,000
Cash Flow Statement
Item 20192020
Net cash from operating activities -55,212-103,425
Net cash from investing activities -104,990-955,483
Net cash from financing activities 302,886973,687
Net increase in cash 142,684-85,221
Depreciation of PP&E 14,52517,787
Amortisation of intangible assets 2,0442,066
Purchase of PP&E -18,622-25,294
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 14.32
First Day OpenHK$ 15.52
First Day Change-14.76%
First Day Volume41422900.0
First Day Turnover620468000.0
Use of Proceeds
1、約621.3百萬港元(占所得款項凈額的32.0%)將用于我們截至最后實際可行日期由25種候選藥物組成的龐大管線中兩種核心產品的臨床開發及商業化; 2、約893.1百萬港元(占所得款項凈額的46.0%)將用于為我們的其他在研候選藥物的持續研發活動及商業化提供資金; 3、約135.9百萬港元(占所得款項凈額的7.0%)將用于我們位于南沙的先進生產設施進行生產線擴張,以籌備未來年度的產品上市; 4、約97.1百萬港元(占所得款項凈額的5.0%)將用于為我們的業務開發活動及在研藥物的擴展提供資金; 5、約194.2百萬港元(占所得款項凈額的10.0%)將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Jefferies Hong Kong Limited CE ATS546
Overall Coordinators (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Jefferies Hong Kong Limited CE ATS546 海通国际证券有限公司 CE AAF806 香港上海汇丰银行有限公司 CE AAA523
Joint Bookrunners (8)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Jefferies Hong Kong Limited CE ATS546 海通国际证券有限公司 CE AAF806 香港上海汇丰银行有限公司 CE AAA523 Fosun International Securities Limited CE AAF432 MACQUARIE CAPITAL LIMITED CE AAC534 SPDB International Capital Limited CE BFZ375 VMS Securities Limited CE AAC621
Joint Lead Managers (8)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Jefferies Hong Kong Limited CE ATS546 海通国际证券有限公司 CE AAF806 香港上海汇丰银行有限公司 CE AAA523 Fosun International Securities Limited CE AAF432 MACQUARIE CAPITAL LIMITED CE AAC534 SPDB International Capital Limited CE BFZ375 VMS Securities Limited CE AAC621

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 CaaS Capital Master Fund LP 38,883,600 HKD — 1.87% — 6 months 2021-10-29
2 GIC Private Limited 38,883,600 HKD — 1.87% — 6 months 2021-10-29
3 Golden Valley Global Limited 38,883,600 HKD — 1.87% — 6 months 2021-10-29
4 Jennison Associates LLC 38,883,600 HKD — 1.87% — 6 months 2021-10-29
5 Mass Ave Global, Inc. 38,883,600 HKD — 1.87% — 6 months 2021-10-29
6 Matthews Asia Funds 116,667,600 HKD — 5.62% — 6 months 2021-10-29
7 OrbiMed Funds 38,883,600 HKD — 1.87% — 6 months 2021-10-29
8 VMS Zhaoke Investment Fund SP 77,775,600 HKD — 3.75% — 6 months 2021-10-29

Directors & Management

PositionChinese nameEnglish Name
Chairman李小羿—
Company Secretary邱淑欣—
No director data available.

Major Shareholders

Major Shareholders & Holdings李氏大藥廠持有約26.2%權益,為單一最大股東;GIC Private Limited透過其受控法團持有13.3%;其他主要股東包括Panacea Venture Healthcare Fund I, L.P.(6.2%)、VMS Holdings Limited(5.8%)、COFL Holdings Limited(5.7%)及TPG Asia VII SF Pte. Ltd.(5.7%)等。
About this page

This page shows Zhaoke Ophth-B (06622) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect